Voloridge Investment Management, LLC Immuno Gen, Inc. Transaction History

Voloridge Investment Management, LLC

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 14, 2024	BUY	$12.46 - $29.95 $8.83 Million - $21.2 Million	708,980 Added 28.22%	3,221,231 $95.5 Million
Q3 2023 Nov 14, 2023	BUY	$14.09 - $19.87 $6.78 Million - $9.56 Million	481,296 Added 23.7%	2,512,251 $39.9 Million
Q2 2023 Aug 14, 2023	BUY	$3.75 - $20.05 $7.62 Million - $40.7 Million	2,030,955 New	2,030,955 $38.3 Million
Q4 2021 Feb 14, 2022	SELL	$4.75 - $7.5 $954,161 - $1.51 Million	-200,876 Closed	0 $0
Q3 2021 Nov 15, 2021	SELL	$5.02 - $6.59 $287,294 - $377,145	-57,230 Reduced 22.17%	200,876 $1.14 Million
Q2 2021 Aug 16, 2021	BUY	$5.79 - $8.6 $1.49 Million - $2.22 Million	258,106 New	258,106 $1.7 Million
Q2 2020 Aug 14, 2020	SELL	$3.32 - $5.34 $414,253 - $666,298	-124,775 Closed	0 $0
Q1 2020 May 15, 2020	BUY	$2.12 - $6.8 $110,770 - $355,300	52,250 Added 72.04%	124,775 $425,000
Q4 2019 Feb 14, 2020	BUY	$2.25 - $5.8 $8,919 - $22,991	3,964 Added 5.78%	72,525 $370,000
Q3 2019 Nov 14, 2019	BUY	$2.22 - $3.39 $152,205 - $232,421	68,561 New	68,561 $166,000
Q2 2019 Aug 14, 2019	SELL	$1.8 - $3.3 $493,768 - $905,242	-274,316 Closed	0 $0
Q1 2019 May 15, 2019	BUY	$2.41 - $5.91 $661,101 - $1.62 Million	274,316 New	274,316 $743,000

1.41M

Ticker IMGN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 220,712,992
Description
ImmunoGen, Inc., a clinical-stage biotechnology company, develops antibody-drug conjugate (ADC) therapies to treat cancer. The company's product candidates include mirvetuximab soravtansine, an ADC targeting folate-receptor alpha (FRa), which is in Phase III clinical trial for the treatment of platinum-resistant ovarian cancer; and Pivekimab sun...

Get notified when there are updates to the investment portfolio of Voloridge Investment Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Voloridge Investment Management, LLC with notifications on news.